HepQuant to Present at 10th Annual Biotech Showcase
Senior Executives Will Also Attend the J.P. Morgan Healthcare Conference
DENVER (December 13th, 2017) — HepQuant, LLC, a Greenwood Village, Colo.-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced it is scheduled to present at the 10th Annual Biotech Showcase, being held on January 8th – 10th, 2018 at the Hilton San Francisco Union Square in San Francisco, CA. The biotech showcase is an investor and partnering conference for private and public biotechnology companies. Details about HepQuant’s presentation are as follows:
Where: Hilton San Francisco Union Square
Date: Wednesday, January 10th, 2018
Time: 1:45 p.m.
Track: Yosemite C – Ballroom level
Senior executives at HepQuant will be available for one-on-one meetings for attendees at the biotech showcase. Senior executives will also be attending the 36th Annual J.P. Morgan Conference and available to meet from Monday, January 8th – Thursday, January 11th.
About HepQuant
Headquartered in Greenwood Village, Colorado, HepQuant, LLC, is a privately-held, early-stage combination drug and in-vitro diagnostic company. HepQuant’s products are investigational combination drug and in-vitro diagnostic devices and have not yet been evaluated or reviewed by the US Food and Drug Administration (FDA) for commercial sale. They are currently available for investigational use via the FDA IDE application process. For additional information, please visit our website at www.hepquant.com.
INVESTOR CONTACT
Brad Everson, Chief Business Development Officer
Ph: (303) 923-2150 | E: brad.everson@hepquant.com
MEDIA CONTACT
Tom Kennedy
E: tkennedy@hepquant.com | M: (720) 507-4164